GlassScriptPhysician profile
Christine Farren
NPI 1790137644
$2,005.17
in general payments reported to CMS, 2019-2025
33 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $490 · 2023: $286 · 2024: $764 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,366 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,365.72 |
| Education | $149.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $326.18 | 2022-2025 | Reblozyl, Opdivo, Augtyro |
| Novartis Pharmaceuticals Corporation | $201.23 | 2022-2025 | |
| Glaxosmithkline, LLC. | $194.53 | 2023-2024 | Jemperli, Zejula, Ojjaara |
| Pfizer INC. | $145.58 | 2024-2025 | |
| Beigene USA, INC. | $125.00 | 2022 | |
| Gilead Sciences, INC. | $118.69 | 2022-2025 | Trodelvy |
| Seagen INC. | $99.95 | 2022 | |
| Incyte Corporation | $88.92 | 2024-2025 | Jakafi |
| Abbvie INC. | $65.77 | 2024-2025 | |
| Genentech USA, INC. | $61.59 | 2022-2025 | Polivy, Phesgo, Lunsumio |
| Celgene Corporation | $52.12 | 2022-2025 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $50.35 | 2022-2023 | Libtayo |
| Merck Sharp & Dohme LLC | $48.23 | 2023-2025 | Keytruda, Lynparza |
| Kite Pharma, INC. | $35.55 | 2023-2025 | Yescarta |
| Karyopharm Therapeutics INC. | $34.15 | 2025 | Xpovio |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $33.65 | 2022-2024 | |
| Geron Corporation | $31.86 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $30.27 | 2022-2024 | Fruzaqla |
| Aveo Pharmaceuticals, INC. | $27.78 | 2022 | |
| Daiichi Sankyo INC. | $27.35 | 2022-2023 | Enhertu |
| Progenics Pharmaceuticals, INC. | $18.96 | 2022 | |
| Servier Pharmaceuticals LLC | $18.73 | 2024 | |
| Mirati Therapeutics, INC. | $18.07 | 2024 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $16.66 | 2023 | Imbruvica |
| Puma Biotechnology, INC. | $16.62 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $16.41 | 2023 | Lynparza |
| Sumitomo Pharma America, INC. | $15.05 | 2023 | Orgovyx |
| Array Biopharma INC | $14.89 | 2022 | |
| Emd Serono, INC. | $14.77 | 2024 | |
| Legend Biotech USA INC. | $14.40 | 2024 | |
| Eisai INC. | $14.25 | 2022 | |
| Pharmacosmos Therapeutics INC. | $13.91 | 2025 | Monoferric |
| Janssen Biotech, INC. | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Farren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.